DHATRYADI KWATHA ORALLY AND FALGU PATRA SWARASA APPLICATION WITH AND WITHOUT VIRECHANA IN SHWITRA(VITILIGO)

A COMPARATIVE CLINICAL STUDY ON DHATRYADI KWATHA AND EXTERNAL APPLICATION OF FALGU PATRA SWARASA ALONG WITH VIRECHANA IN THE MANAGEMENT OF SHWITRA W.S.R. TO VITILIGO - SHWITRA

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/04/006785

Enrollment

Registered

2016-04-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Depigmented macules. Hypo pigmented skin lesions. classical symptoms of Shwitra Health Condition 2: L80- Vitiligo

Interventions

Intervention1: Virechana karma followed by Dhatrayadi kwatha and external application of Falgu patra swarasa: Classical Virechana karma Internal Drugs: Dhatryadi kwatha- 40ml twice a day. External: Fa

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having sign and symptoms of Shwitra (Vitiligo). 2. Patients indicated for Virechana as per Ayurvedic classics. 3. If the patients to withdrawn ongoing medications like systemic corticosteroids, systemic or local photosensitizers or drugs scientifically proven to cause hyperpigmentation on local application or systemic administration will be included. Washout period after quitting will be for 7 days.

Exclusion criteria

Exclusion criteria: 1.Patients having chronic condition, more than 10 years 2.Patients contraindicated for Virechana as per Ayurvedic classics. 3.Patients having all other de-pigmentory disorders. 4.Patients having serious cardiac, renal, hepatic diseases. 5.Patients having major illness like IDDM, NIDDM which are poorly controlled and any other systemic diseases. 6.Patches due to burning, chemical explosion etc. 7.Located at region of Guhya(Genital region), Panitala(Foot soles and Hand soles), Oshtha (Lips), Aekanga, Sarvanga(whole body). 8.Patches with Raktaroma & sansakta. 9.Patients with known drug hypersensitivity, photosensitivity, 10.Pregnant and lactating women. 11.Patients with ongoing medications like systemic corticosteroids, systemic or local photosensitizers or drugs scientifically proven to cause hyperpigmentation on local application or systemic administration.

Design outcomes

Primary

Measure	Time frame
ASSESSMENT WILL BE DONE ON THE SPECIALLY DESIGNED PROFORMA OR ASSESSING SIGN AND SYMPTOMS IN SCORING PATTERNTimepoint: 2 MONTHS	—

Secondary

Measure	Time frame
ASSESSMENT WILL BE DONE ON THE SPECIALLY DESIGNED PROFORMA OR ASSESSING SIGN AND SYMPTOMS IN SCORING PATTERNTimepoint: 2 MONTHS	—

Countries

India

Contacts

Public ContactProf P K Prajapati

Institute for Post Graduate Teaching and Research in Ayurveda

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026